COVID-19: Drugs in Development


The COVID-19 outbreak, which started in December 2019 in Wuhan City, China, was declared a "Public Health Emergency of International Concern" by the WHO on January 30, 2020. The outbreak was characterized as a pandemic on March 11, 2020.

Currently, there are no drugs to treat COVID-19, caused by the novel coronavirus SARS-CoV-2.

Listed below are companies that are in the race to find a treatment or vaccine for the novel coronavirus.

Subscribe to RTT Intelligent Investor for FREE 7-Day Trial with complete access to COVID-19 Drugs in Development Calendar.

Company Name
Current Stage
Next Milestone
Last Updated
Eli Lilly And Co.
LY-CoV555, also known as Bamlanivimab
LY-CoV555 an antibody therapeutic is being developed for treatment and prevention of COVID-19.

Phase 3 trial OF LY-CoV555 for the prevention of SARS-CoV-2 infection and COVID-19 (BLAZE-2)

On Nov.9, 2020, FDA issued emergency use authorization for Bamlanivimab for the treatment of mild-to-moderate COVID-19 in adult and pediatric patients.
AbCellera Biologics Inc., National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center
capmatinib- Repurposed
Announced capmatinib showed robust antiviral effects in experimental Covid-19 models.
Ryerson University
The Vector Institute
Adagio Therapeutics, Inc.
Started Phase 1/2/3 study in high-risk people with mild to moderate COVID-19.
Phase 2/3 study to start in the second half of 2021.
Eli Lilly And Co.
LY-CoV555, also known as Bamlanivimab
Phase 2 trial of LY3819253, alone or in combination with either LY3832479 or VIR-7831 in low-risk adults with COVID-19 (BLAZE-4) began in Jan.2020
-- Positive results from BLAZE-4 trial reported on Mar.29,2021
Vir Biotechnology and GSK
DYAI-100 advancing towards first-in-human Phase 1 clinical trial
ImmunoPrecise Antibodies Ltd.
Out of 27 antibodies screened, 23-H7 has been identified as the one with a potential to fight SARS-CoV-2 variants of concern
Laurent Pharmaceuticals
The independent Data Safety Monitoring Board (DSMB) for the phase 2 study of LAU-7b, dubbed Resolution, recommended to continue the study without modification.
Top line results are expected in the second half of 2021.
Aimmune Therapeutics Inc.
Ampligen as a potential prophylaxis or treatment for COVID-19
-- Positive safety data in 1st cohort of phase I study of Intranasal Ampligen as potential prophylaxis or treatment for COVID-19 reported on Apr.7, 2021

--Phase 1 study of Ampligen as a potential intranasal therapy in healthy subjects
Commencement of Phase 2 studies

Get Full Access to latest records of COVID-19 Drugs in Development Calendar by subscribing to RTT Intelligent Investor with FREE 7-Day Trial. (No Credit Card Required)

Editors Pick
Pfizer Inc. and BioNTech SE Monday announced that they will supply an additional 100 million doses of COMIRNATY, the companies' COVID-19 vaccine, to the 27 European Union member states in 2021. The agreement follows the European Commission's decision to exercise its option to purchase an additional 100 million doses under its expanded Advanced Purchase Agreement signed on February 17. Prineville, Oregon-based Creative Foods Inc. is recalling two Bueno coffee substitute gluten-free products for the possible presence of undeclared allergens, the U.S. Food and Drug Administration said. The recall involves Bueno Coffee Substitute Creamy Hazelnut and Bueno Coffee Substitute Pecan Praline. They both may contain undeclared peanut, hazelnut, and/or barley, which contains gluten. Toyota has unveiled an all-electric SUV concept named "Toyota bZ4X Concept." It is the first of a new battery electric vehicle or BEV line-up under the new Toyota "bZ" - Beyond Zero brand.